Insider · CIK 0002008983
Ashwath Jayagopal
officer
Files at IRD (Opus Genetics, Inc.). First filing Mar 18, 2026, latest Mar 18, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $19k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRD: Opus Genetics, Inc.
IRDOct 9, 2026 · close 4.65
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Opus Genetics, Inc. | $19k 3,719 shares | -1% | +631% from low0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | IRD Opus Genetics, Inc. | SOpen-market sale Common Stock | -3,719 | $5.12 | $19k | 516,775 | Mar 18, 2026 |
| Feb 12, 2026 | IRD Opus Genetics, Inc. | FTax withholding Common Stock | -5,313 | $3.39 | $18k | 520,494 | Feb 17, 2026 |
| Jan 22, 2026 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 525,807 | Jan 26, 2026 |
| Mar 13, 2025 | IRD Opus Genetics, Inc. | AGrant or award Common Stock | +52,500 | $0.00 | $0 | 125,807 | Mar 17, 2025 |
| Mar 13, 2025 | IRD Opus Genetics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +52,500 | $0.00 | $0 | 52,500 | Mar 17, 2025 |
| Feb 13, 2025 | IRD Opus Genetics, Inc. | FTax withholding Common Stock | -5,193 | $1.15 | $5,972 | 73,307 | Feb 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.